KR101158447B1 - 폴리펩타이드의 생산 - Google Patents

폴리펩타이드의 생산 Download PDF

Info

Publication number
KR101158447B1
KR101158447B1 KR1020077004807A KR20077004807A KR101158447B1 KR 101158447 B1 KR101158447 B1 KR 101158447B1 KR 1020077004807 A KR1020077004807 A KR 1020077004807A KR 20077004807 A KR20077004807 A KR 20077004807A KR 101158447 B1 KR101158447 B1 KR 101158447B1
Authority
KR
South Korea
Prior art keywords
medium
glutamine
culture
delete delete
cell culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020077004807A
Other languages
English (en)
Korean (ko)
Other versions
KR20070085220A (ko
Inventor
데니스 드라포
옌-퉁 루안
제임스 알 머서
웬지 왕
다니엘 알 라스코
Original Assignee
와이어쓰 리서치 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101158447(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 와이어쓰 리서치 아일랜드 리미티드 filed Critical 와이어쓰 리서치 아일랜드 리미티드
Publication of KR20070085220A publication Critical patent/KR20070085220A/ko
Application granted granted Critical
Publication of KR101158447B1 publication Critical patent/KR101158447B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/22—Zinc; Zn chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077004807A 2004-08-27 2005-08-26 폴리펩타이드의 생산 Expired - Lifetime KR101158447B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US60494104P 2004-08-27 2004-08-27
US60507404P 2004-08-27 2004-08-27
US60509704P 2004-08-27 2004-08-27
US60/605,097 2004-08-27
US60/605,074 2004-08-27
US60/604,941 2004-08-27
PCT/US2005/030437 WO2006026445A1 (en) 2004-08-27 2005-08-26 Production of polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117006936A Division KR20110036780A (ko) 2004-08-27 2005-08-26 폴리펩타이드의 생산

Publications (2)

Publication Number Publication Date
KR20070085220A KR20070085220A (ko) 2007-08-27
KR101158447B1 true KR101158447B1 (ko) 2012-06-20

Family

ID=35482353

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020077004807A Expired - Lifetime KR101158447B1 (ko) 2004-08-27 2005-08-26 폴리펩타이드의 생산
KR1020117006936A Ceased KR20110036780A (ko) 2004-08-27 2005-08-26 폴리펩타이드의 생산

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117006936A Ceased KR20110036780A (ko) 2004-08-27 2005-08-26 폴리펩타이드의 생산

Country Status (20)

Country Link
US (1) US7294484B2 (enExample)
EP (2) EP1789571B1 (enExample)
JP (1) JP4864892B2 (enExample)
KR (2) KR101158447B1 (enExample)
CN (2) CN102827905B (enExample)
AR (2) AR051017A1 (enExample)
AU (1) AU2005280034B2 (enExample)
BR (1) BRPI0514703A (enExample)
CA (1) CA2578141C (enExample)
CR (1) CR8997A (enExample)
EC (1) ECSP077353A (enExample)
EG (1) EG26462A (enExample)
ES (1) ES2628012T3 (enExample)
IL (1) IL181589A0 (enExample)
MX (1) MX2007002380A (enExample)
NO (1) NO342433B1 (enExample)
SG (2) SG190674A1 (enExample)
TW (1) TWI384069B (enExample)
WO (1) WO2006026445A1 (enExample)
ZA (1) ZA200702483B (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SG155183A1 (en) * 2005-08-26 2009-09-30 Ares Trading Sa Process for the preparation of glycosylated interferon beta
PE20070796A1 (es) * 2005-10-24 2007-08-15 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
US20070231895A1 (en) * 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US8604175B2 (en) * 2005-12-09 2013-12-10 Ares Trading S.A. Method for purifying FSH or a FSH mutant
ES2790887T3 (es) 2006-01-04 2020-10-29 Baxalta Inc Medio de cultivo celular sin oligopéptidos
CN101496387B (zh) 2006-03-06 2012-09-05 思科技术公司 用于移动无线网络中的接入认证的系统和方法
ES2668212T3 (es) * 2006-07-13 2018-05-17 Wyeth Llc Producción de factor de coagulación IX con patrón de glucosilación mejorado
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
JP5401319B2 (ja) * 2006-11-03 2014-01-29 ワイス・エルエルシー 細胞培養における解糖阻害物質
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
PL2115126T3 (pl) * 2007-03-02 2015-08-31 Wyeth Llc Zastosowanie miedzi i glutaminianu w hodowli komórkowej do wytwarzania polipeptydów
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
CN105567627B (zh) 2007-04-26 2020-09-29 中外制药株式会社 使用含高浓度氨基酸的培养基的细胞培养方法
WO2009023562A2 (en) 2007-08-09 2009-02-19 Wyeth Use of perfusion to enhance production of fed-batch cell culture in bioreactors
US8319819B2 (en) 2008-03-26 2012-11-27 Cisco Technology, Inc. Virtual round-table videoconference
HUE027035T2 (hu) * 2008-04-17 2016-08-29 Wyeth Llc Eljárások csont morfogenetikus fehérjék termelésének fokozására
SI2326720T1 (en) 2008-09-15 2018-06-29 F. Hoffmann-La Roche Ag Substances and procedures for regulating cellular osmolality
US8694658B2 (en) 2008-09-19 2014-04-08 Cisco Technology, Inc. System and method for enabling communication sessions in a network environment
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
RU2551237C2 (ru) 2008-10-20 2015-05-20 Эббви Инк Инактивация вируса при очистке антител
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
FI2464725T4 (fi) 2009-08-11 2025-03-21 Hoffmann La Roche Proteiinien tuotanto glutamiinittomassa soluviljelyn elatusaineessa
GB0917647D0 (en) * 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
EP2523971B1 (en) * 2010-01-13 2015-02-25 APT Therapeutics, Inc. Therapeutic apyrase constructs, apyrase agents, and production methods
US20110262965A1 (en) 2010-04-23 2011-10-27 Life Technologies Corporation Cell culture medium comprising small peptides
RU2563353C2 (ru) 2010-04-26 2015-09-20 Новартис Аг Улучшенная среда для культивирования клеток
PT2563904E (pt) * 2010-04-26 2015-05-12 Novartis Ag Meio de cultura de células aperfeiçoado
LT3330370T (lt) 2010-04-26 2021-06-10 Novartis Ag Cho ląstelių auginimo būdas
HRP20250948T1 (hr) 2010-07-08 2025-10-10 Takeda Pharmaceutical Company Limited Postupak proizvodnje rekombinantnog visokomolekulskog vwf u kulturi stanica
CN103080300B (zh) 2010-08-05 2015-11-25 安姆根有限公司 增加细胞培养物的产率和活力的二肽
CA2807607A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
CN102382794B (zh) * 2010-09-01 2013-09-18 山东新时代药业有限公司 一种哺乳动物细胞的灌流培养方法
US8599865B2 (en) 2010-10-26 2013-12-03 Cisco Technology, Inc. System and method for provisioning flows in a mobile network environment
US9143725B2 (en) 2010-11-15 2015-09-22 Cisco Technology, Inc. System and method for providing enhanced graphics in a video environment
US8730297B2 (en) 2010-11-15 2014-05-20 Cisco Technology, Inc. System and method for providing camera functions in a video environment
US9338394B2 (en) 2010-11-15 2016-05-10 Cisco Technology, Inc. System and method for providing enhanced audio in a video environment
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR101591671B1 (ko) 2011-04-29 2016-02-04 바이오콘 리서치 리미티드 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법
KR102358951B1 (ko) 2011-07-01 2022-02-08 암젠 인크 포유동물 세포 배양
US8682087B2 (en) 2011-12-19 2014-03-25 Cisco Technology, Inc. System and method for depth-guided image filtering in a video conference environment
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2890782A1 (en) 2012-09-02 2015-07-08 AbbVie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2905010A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AR096839A1 (es) * 2013-07-06 2016-02-03 Cadila Healthcare Ltd Proceso mejorado para la producción de anticuerpos monoclonales
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US11390663B2 (en) 2013-10-11 2022-07-19 Regeneron Pharmaceuticals, Inc. Metabolically optimized cell culture
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
JP2017500017A (ja) * 2013-12-20 2017-01-05 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
CA2937611C (en) 2014-02-27 2023-01-03 F. Hoffmann-La Roche Ag Modulation of cell growth and glycosylation in recombinant glycoprotein production
EP4512889A3 (en) 2014-03-19 2025-05-07 Pfizer Inc. Method of cell culture
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TW202246486A (zh) * 2014-06-09 2022-12-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
LT3227454T (lt) 2014-12-01 2020-07-27 Amgen Inc. Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra
CA2985702A1 (en) * 2015-05-29 2016-12-08 Boehringer Ingelheim International Gmbh Cell-controlled perfusion in continuous culture
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
US10738334B2 (en) 2015-09-23 2020-08-11 Pfizer Inc. Cells having reduced BCAT1
JP7311966B2 (ja) 2015-11-17 2023-07-20 ファイザー・インク 細菌細胞培養物中で多糖を生成するための培地および発酵方法
KR102168981B1 (ko) * 2016-04-05 2020-10-22 화이자 인코포레이티드 세포 배양 공정
PL3372670T3 (pl) * 2017-03-09 2019-08-30 Evonik Technochemie Gmbh Pożywki hodowlane zawierające dipeptydy n-acylo-x-glutaminy
GB201708655D0 (en) 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
KR102190790B1 (ko) * 2018-10-19 2020-12-15 주식회사 프로젠 변형된 egf 단백질의 생산 방법
CN111836826B (zh) 2017-10-23 2024-01-02 普罗根有限公司 修饰的egf蛋白，其制备方法及其用途
EP3717656B1 (en) * 2017-11-30 2024-03-13 F. Hoffmann-La Roche AG Process for culturing mammalian cells
IL307155B2 (en) 2018-05-01 2025-11-01 Amgen Inc Antibodies with modulated glycan profiles
JP7599418B2 (ja) 2018-11-13 2024-12-13 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の生成中の微量金属の制御
CA3121884A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN113025648B (zh) * 2019-12-09 2023-06-02 广东菲鹏制药股份有限公司 Expi293细胞瞬时表达目标蛋白的方法及其应用
US12163122B2 (en) 2020-08-31 2024-12-10 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2022060169A (ja) 2020-10-02 2022-04-14 ファイザー・インク Ｒｓｖ ｆタンパク質生産のための細胞培養工程
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
JP2022184798A (ja) 2021-06-01 2022-12-13 ファイザー・インク ｓＦＧＦＲ３ポリペプチドを生産するための細胞培養方法
KR20240090312A (ko) 2021-10-07 2024-06-21 리제너론 파아마슈티컬스, 인크. Ph 미터 보정 및 교정
MX2024004107A (es) 2021-10-07 2024-04-19 Regeneron Pharma Sistemas y metodos para modelar y controlar el ph.
AU2023229164A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production
JP2025517984A (ja) 2022-05-25 2025-06-12 ジェネンテック， インコーポレイテッド 灌流細胞培養のための哺乳動物細胞を調製するための方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024484A1 (en) * 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-lewis y antibodies
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5672502A (en) * 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
WO1991005058A1 (en) 1989-10-05 1991-04-18 Glenn Kawasaki Cell-free synthesis and isolation of novel genes and polypeptides
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5538983A (en) * 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
US5156964A (en) 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
GB2251249B (en) 1990-12-28 1995-06-21 Mogam Biotech Res Inst High-density medium for animal cell culture
GB9118664D0 (en) 1991-08-30 1991-10-16 Celltech Ltd Cell culture
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DE4313620A1 (de) * 1993-04-26 1994-10-27 Biotechnolog Forschung Gmbh Hamsterzellinien und Verfahren zur Glykoproteingewinnung
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US5856179A (en) * 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5721121A (en) * 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US20020012991A1 (en) * 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
CA2354862A1 (en) 1998-10-19 2000-04-27 Yeda Research And Development Co. Ltd. Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
WO2002088307A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
ATE420114T1 (de) 2001-04-30 2009-01-15 Lilly Co Eli Humanisierte antikörper die das beta-amyloid peptid erkennen& x9;
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
IL163525A0 (en) 2002-02-21 2005-12-18 Wyeth Corp A follistatin domain containing protein
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BR122019027966B8 (pt) 2002-05-02 2021-07-27 Wyeth Corp conjugado monomérico de derivado de caliqueamicina/anti-corpo anti-cd22 e uso dos mesmos
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US20040223966A1 (en) 2002-10-25 2004-11-11 Wolfman Neil M. ActRIIB fusion polypeptides and uses therefor
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024484A1 (en) * 1994-03-08 1995-09-14 Scotgen Biopharmaceuticals, Inc. Recombinant humanized anti-lewis y antibodies
WO2002101019A2 (en) * 2001-06-13 2002-12-19 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
WO2004037861A2 (en) * 2002-10-22 2004-05-06 Wyeth Neutralizing antibodies against gdf-8 and uses therefor

Also Published As

Publication number Publication date
KR20070085220A (ko) 2007-08-27
SG190674A1 (en) 2013-06-28
CA2578141C (en) 2013-01-08
EP1789571B1 (en) 2017-04-26
AR051017A1 (es) 2006-12-13
CR8997A (es) 2007-08-28
WO2006026445A1 (en) 2006-03-09
EG26462A (en) 2013-11-13
CN101048511B (zh) 2012-07-18
CN101048511A (zh) 2007-10-03
JP4864892B2 (ja) 2012-02-01
JP2008511329A (ja) 2008-04-17
NO20071572L (no) 2007-05-23
AU2005280034B2 (en) 2012-06-21
EP2357250B1 (en) 2021-10-06
US20060121568A1 (en) 2006-06-08
EP2357250A3 (en) 2014-07-02
AR086932A2 (es) 2014-01-29
MX2007002380A (es) 2007-06-15
KR20110036780A (ko) 2011-04-08
EP2357250A2 (en) 2011-08-17
SG158092A1 (en) 2010-01-29
IL181589A0 (en) 2007-07-04
AU2005280034A1 (en) 2006-03-09
CA2578141A1 (en) 2006-03-09
TWI384069B (zh) 2013-02-01
EP1789571A1 (en) 2007-05-30
US7294484B2 (en) 2007-11-13
CN102827905B (zh) 2016-08-31
ECSP077353A (es) 2007-05-30
ZA200702483B (en) 2018-11-28
CN102827905A (zh) 2012-12-19
ES2628012T3 (es) 2017-08-01
NO342433B1 (no) 2018-05-22
BRPI0514703A (pt) 2008-06-24

Similar Documents

Publication Publication Date Title
KR101158447B1 (ko) 폴리펩타이드의 생산
KR100998857B1 (ko) 항-아밀로이드 베타 항체의 생산
KR100988451B1 (ko) ＴＮＦＲ-Ｉｇ 융합 단백질의 제조
HK1180013B (en) Production of polypeptides
HK1181073A (en) Production of tnfr-ig fusion protein
HK1180013A (en) Production of polypeptides
AU2012200353A1 (en) PRODUCTION OF a-ABeta

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070227

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20100326

Comment text: Request for Examination of Application

A302 Request for accelerated examination
PA0302 Request for accelerated examination

Patent event date: 20100329

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20100615

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20101124

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20100615

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20110224

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20101124

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20120321

Appeal identifier: 2011101001426

Request date: 20110224

A107 Divisional application of patent
AMND Amendment
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20110325

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20110325

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20110224

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20100914

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20100326

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20070426

Patent event code: PB09011R02I

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110429

Patent event code: PE09021S01D

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20120321

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20110402

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20120614

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20120615

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160330

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20160330

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20170330

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20170330

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20180329

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20180329

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20190327

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20190327

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20200324

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20210329

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20240527

Start annual number: 13

End annual number: 13